Resources

Engitix announced the appointment of Sonia Quaratino, MD, PhD in the newly created role of Executive Vice President (EVP) Chief Medical Officer (CMO).

PACE and the UK Health Security Agency (UKHSA) have released five new contemporary antimicrobial resistance (AMR) strain panels, giving innovators worldwide a resource to test novel therapeutics and diagnostics against today’s resistance patterns

Regional cluster updates, fresh OLS data, NICE's Enhertu approval and £89.9m for Chemify - catch up on this week's CEO blog.

Global drug development consultancy Boyds has reported robust revenue growth for the financial year ending March 2026, despite the slowdown in the global biotech and pharma markets.

Analysis for Innovators (A4I) is a funding programme that helps UK SMEs overcome complex measurement, testing and analysis challenges by providing access to world-class expertise, specialist facilities and scientific knowledge from leading UK measurement organisations, including NML.

Causeway Sensors and Fusion Antibodies share a case study on how TITAN’s real-time, at-line analytics detected key harvest yield differences by Day 3, enabling early process intervention and smarter resource allocation.

Coulter Partners, the global advisor building leadership teams for Health, Science and Technology innovation businesses, today announces the appointment of Carlos Gómez-Arnau, Doug Roberts, and Stuart Penney as Client Partners. These strategic hires further strengthen the firm's international presence and reinforce its commitment to supporting clients across key healthcare, life sciences, and biotechnology markets.

Brainomix, a global leader in AI-powered medical imaging, today announced that it has been selected to join Future Fifty, the UK’s most prestigious scale-up programme, recognizing the company as one of the country’s most high-potential technology businesses.

New appointments support MDC’s mission to turn drug discovery into commercial breakthroughs

Autumn Budget, AI regulation and new transatlantic partnerships: how we’re driving scale and capital for UK biotechs.

Peptide drug discovery uses peptides to investigate biological targets and develop potential therapeutics. The blog covers their key advantages, applications in screening and SAR, major challenges such as stability and delivery, optimisation strategies, and how o2h Discovery supports peptide synthesis and drug discovery workflows.

The NML has published its Annual Review 2025, reflecting on a year of scientific achievement, collaboration and investment in the future of UK chemical and biological measurement science. The Review showcases how the NML’s trusted measurement expertise is enabling innovation to be translated into real-world impact, supporting UK growth and regional expertise, and strengthening public confidence in policy and government decisions. If you would like to discuss any of the work featured in this Review or explore future collaboration opportunities with the NML, please contact [email protected]

Join Winston Taylor and Raymond James on 23rd September 2026 in London, as we bring together leaders who've built, scaled, and exited growth-stage businesses. A sharp, practical discussion on the routes to growth, liquidity, and exit.

UK Life Sciences Innovation Signals Report (H1 2026) explores how effectively the UK is converting scientific innovation into commercial growth, healthcare adoption, and patient impact. The report assesses three critical areas: Capital, Capability, and Conversion, revealing that while investment remains strong (£2.83bn raised in H1 2026) and research capabilities continue to improve, the sector's biggest challenge is turning innovation into widespread adoption across healthcare systems and markets. Key findings show that funding is increasingly concentrated in a small number of high-conviction companies, regulatory and clinical trial processes are becoming more efficient, and NHS adoption of new innovations is improving but remains inconsistent. The report provides valuable insights for founders, CFOs, investors, and industry leaders looking to understand the trends, opportunities, and challenges shaping the future of UK life sciences.

Precision BioSearch partners with Cytospire Therapeutics to appoint Sumeet Ambarkhane as CMO

Pioneer Group and Oxford Properties have announced that Syncona Investment Management Ltd (SIML), a leading life science investment manager, is moving into Victoria House, a leading hub for life sciences in London.

IMU Biosciences has formed a strategic partnership with Eurofins Transplant Genomics, with an exclusive licensing agreement to give the company access to IMU’s proprietary HD Immunology platform for transplant-related clinical development programmes.

What do the six most dangerous hospital superbugs have in common, and what makes each one distinct? MORF-Bio's live webinar compares all six genomes to find out.